Oncology

Live Report from ASH:
Ibritumomab Provides Benefit in Patients with Follicular Lymphoma

December 11, 2007
Anton Hagenbeek
Anton Hagenbeek

ANTON HAGENBEEK, University Medical Centre Utrecht
For patients with advanced-stage follicular non-Hodgkin’s lymphoma, ibritumomab tiuxetan seems to prolong progression free survival by two years with favourable toxicity. Sarah Maxwell spoke to study author Anton Hagenbeek at the ASH meeting in Atlanta while George Canellos provided comment.

ASCO Logo Live Report from ASH:<br />Ibritumomab Provides Benefit in Patients with Follicular Lymphoma

Download this interview

Add podcast to iTunes

Similar Interviews

  • Radio-Labelled Antibodies: Big Benefits in Follicular Lymphoma?

    • Timothy Illidge Reporting From: 4th European Congress on Hematologic Malignancies, Paris 22-24 February, 2008 TIMOTHY

  • Rituximab Maintenance after Chemotherapy Gives Better Outcomes in Advanced Follicular Lymphoma

    • Sandra Horning Abstract 349 Sandra Horning, Stanford University Medical Center It is not necessary to use rituximab along with standard CVP (cyclophosphamide, vincristine,

  • Audio Journal of Hematologic Malignancy Special Edition 2005

    • Reporting from: - Annual Meeting of the American Society of Hematology, December 4-7, 2004, San Diego - Lymphoma: The Next Questions,

    Post a comment